Primary Immunodeficiency Diseases clinical trials at University of California Health

6 research studies open to eligible people

Showing trials for

  • About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

    open to eligible people ages 2 years and up

    The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and pediatric participants with PIDD and compare them to HYQVIA in participants 16 years old and older. The participants will be treated with TAK-881/HYQVIA or HYQVIA/TAK-881 with the same dose and dosing interval of immunoglobulin for up to 51 weeks (for participants greater than or equal to [>=]16 years) and only with TAK-881 for up to 27 weeks (for participants aged 2 to less than [<]16 years) as they were treated with another immunoglobulin before enrollment. Participants will need to visit the clinic every 3 or 4 weeks during the duration of the study.

    at UC Irvine

  • Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

    open to all eligible people

    The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.

    at UC Davis UCLA

  • Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

    open to eligible people ages 1 month to 79 years

    Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

    at UCLA UCSF

  • EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

    open to eligible people ages 1 month to 79 years

    Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

    at UCLA UCSF

  • Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

    open to eligible people ages 1 month to 79 years

    BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be safe and effective in decreasing specific viral load in children, adolescents and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).

    at UCSF

  • Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

    open to eligible people ages 1 month to 79 years

    CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

    at UCSF

Our lead scientists for Primary Immunodeficiency Diseases research studies include .

Last updated: